13.8 C
New York
Monday, March 4, 2024

Viking Therapeutics’ stock rallies following early drug study data

Viking Therapeutics’ stock rallies following early drug study data


Viking Therapeutics Inc.
VKTX,
-0.37%

shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clinical study showed its drug candidate reduced liver fat levels. Viking shares rose as much as 7% after hours, following a 0.4% decline to close the regular session at $10.27. The company said a Phase 1 dosing study of its drug candidate VK2735 “showed reductions in subjects’ liver fat content and plasma lipid levels” after 28 days of treatment, compared with a group given a placebo.



Source link

Latest stories